Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.40 |
| ▸ | P2RX2 | Q9UBL9 | 5/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16410285 | 0.95 | SMN1; SMN2 (0.42) | SUCNR1SMN1; SMN2MAPTRAB9AP2RX3 | |
| SCHEMBL16410450 | 0.87 | CFD (0.48) | SUCNR1SMN1; SMN2MAPTRAB9ALMNA | |
| SCHEMBL16409571 | 0.87 | CFD (0.48) | SUCNR1SMN1; SMN2MAPTRAB9ALMNA | |
| SCHEMBL17772668 | 0.86 | SMN1; SMN2 (0.43) | SMN1; SMN2MAPTRAB9AP2RX3P2RX2 | |
| SCHEMBL16397193 | 0.85 | SUCNR1 (0.47) | SUCNR1HDAC1 | |
| SCHEMBL17764462 | 0.81 | SUCNR1 (0.48) | SUCNR1HDAC1 | |
| SCHEMBL16397314 | 0.81 | SUCNR1 (0.49) | SUCNR1HDAC1 | |
| SCHEMBL16396992 | 0.80 | SUCNR1 (0.60) | SUCNR1HDAC1 | |
| SCHEMBL17764426 | 0.80 | MAPT (0.37) | SUCNR1SMN1; SMN2MAPTRAB9AHDAC1 | |
| SCHEMBL16403586 | 0.79 | CFD (0.61) | SUCNR1SMN1; SMN2MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | CFD, CFH, CFB | SUCNR1 4670/4885SMN1; SMN2 4625/4885MAPT 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.